We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience, read our Cookie Policy
EP38767
Abstract: Active pharmaceutical ingredients (APIs) are the core of modern pharmaceutical products, and are also the basis of many innovative and effective therapeutic programs that have been applied and are being developed. To comply with these requirements and industry, clinical, and production best practices is absolutely necessary for any participant in the pharmaceutical product supply chain. Quality assurance, clinical trials and user assessment are key parameters for various stakeholders to review.
Summary: The latest USP/ USP-NF API analysis contains the identification of the chemical structure and the examination of validity, impurity and safety. Although USP now has removed and reduced properties test, but it can be used as a supplement to identification.References: Thurman, E. M., & Ferrer, I. (2010). ‘The isotopic mass defect: a tool for limiting molecular formulas by accurate mass.’ Analytical & Bioanalytical Chemistry, 397(7), 2807-2816.
R. Fr?tschl, & L. Müller. (2015). ‘Ich m7: guideline for the assessment and control of dna reactive (mutagenic) impurities in pharmaceuticals to limit carcinogenic risk.’ Bulletin of the School of Oriental & african Studies, 38(3), 658-661.
Niazi, S. K. (2009). ‘Good manufacturing practice guide for active pharmaceutical ingredients. Chapter, 376.’
Guideline, I. (2004). ‘Impurities in new drug substances. Q3a,’ 18(4), 118-122
https://www.alfachemic.com/testinglab/blog/active-pharmaceutical-ingredient-analysis.html
Summary: The latest USP/ USP-NF API analysis contains the identification of the chemical structure and the examination of validity, impurity and safety. Although USP now has removed and reduced properties test, but it can be used as a supplement to identification.References: Thurman, E. M., & Ferrer, I. (2010). ‘The isotopic mass defect: a tool for limiting molecular formulas by accurate mass.’ Analytical & Bioanalytical Chemistry, 397(7), 2807-2816.
R. Fr?tschl, & L. Müller. (2015). ‘Ich m7: guideline for the assessment and control of dna reactive (mutagenic) impurities in pharmaceuticals to limit carcinogenic risk.’ Bulletin of the School of Oriental & african Studies, 38(3), 658-661.
Niazi, S. K. (2009). ‘Good manufacturing practice guide for active pharmaceutical ingredients. Chapter, 376.’
Guideline, I. (2004). ‘Impurities in new drug substances. Q3a,’ 18(4), 118-122
https://www.alfachemic.com/testinglab/blog/active-pharmaceutical-ingredient-analysis.html
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Related Posters
Development of QSP model of COVID-19 based on Immune Response Template
Veronika Musatova, Oleg Demin, Maria Kupriyanova, Anna Viktorenko
Dry Powder Inhalation Excipients
Helen Smith
Penetration Enhancer Excipients
Helen Smith
PBPK modeling of T cell distribution in cancer patients
Dmitry Shchelokov 1, Oleg Demin Jr 1, Sara Brett 2 , Stefan Zajic 3, Lourdes Cucurull-Sanchez 2
Investigation of inflammation during Alzheimer's disease by quantitative systems pharmacology model
Andrey Masliukov, Tatiana Karelina
